Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyAlexander M.M. Eggermont, Alessandro Testori, Paolo A. Ascierto et al.|New England Journal of Medicine|2016Cited by 1.3k
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialAlexander M.M. Eggermont, Alessandro Testori, Vanna Chiarion‐Sileni et al.|The Lancet Oncology|2015Cited by 1.3k
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trialAlexander M.M. Eggermont, Alessandro Testori, Vanna Chiarion‐Sileni et al.|European Journal of Cancer|2019Cited by 181
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trialCorneel Coens, Alexander M.M. Eggermont, Stefan Suciu et al.|The Lancet Oncology|2017Cited by 104